Aqilion on phase I results and potential IPO

10 November, 2023

Aqilion on phase I results and potential IPO

10 November, 2023

Aqilion recently announced positive results from the phase I study with their candidate AQ280. The candidate targets eosinophilic esophagitis and is tested in Aqilion’s Regulus programme. CEO Sarah Fredriksson visited BioStock’s studio to tell us more about the phase I results and the plans for a potential IPO.

See the interview with Aqilion’s CEO Sarah Fredriksson below.

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev

RELATED ARTICLESMORE FROM AUTHOR

Aqilion’s CEO: “We are driven by dealmaking and scientific data”

Aqilion and Merck sever ties

Aqilion aims for best-in-class with new programme

RELATED ARTICLES MORE FROM AUTHOR